金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01548 金斯瑞生物科技

休市中 05-03 16:09:00

12.000

-0.340

-2.76%

最高12.640	最低11.920	成交量589.22万
今开12.540	昨收12.340	日振幅5.83%
总市值254.88亿	流通市值254.88亿	总股本21.24亿
成交额7,203万	换手率0.28%	流通股本21.24亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01548","market":"HK","secType":"STK","nameCN":"金斯瑞生物科技","latestPrice":12,"timestamp":1714723740029,"preClose":12.34,"halted":0,"volume":5892203,"delay":0,"floatShares":2124027670,"shares":2124027670,"eps":-0.3536227,"marketStatus":"休市中","marketStatusCode":7,"change":-0.34,"latestTime":"05-03 16:09:00","open":12.54,"high":12.64,"low":11.92,"amount":72026192,"amplitude":0.058347,"askPrice":12,"askSize":188000,"bidPrice":11.98,"bidSize":10000,"shortable":3,"etf":0,"ttmEps":-0.35390396724948825,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"listingDate":1451404800000,"adjPreClose":12.34,"openAndCloseTimeList":[[1714699800000,1714708800000],[1714712400000,1714723200000]],"volumeRatio":0.4621693169652113,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01548/tweets","defaultTab":"tweets","newsList":[{"id":"2432175506","title":"金斯瑞生物科技(01548)上涨5.15%，报12.24元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2432175506","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2432175506?lang=zh_cn&edition=full","pubTime":"2024-05-02 13:28","pubTimestamp":1714627682,"startTime":"0","endTime":"0","summary":"5月2日，金斯瑞生物科技(01548)盘中上涨5.15%，截至13:28，报12.24元/股，成交3891.85万元。金斯瑞生物科技股份有限公司是一家全球重要的生命科学研发与生产服务提供商，主要业务包括生命科学服务及产品、生物医药合同研发生产、工业合成产品和综合性全球细胞疗法。截至2022年12月31日，公司在全球拥有6213名员工，拥有超过210项授权专利与800多项专利申请，业务覆盖全球100多个国家和地区，为20余万客户提供服务与产品。截至2023年年报，金斯瑞生物科技营业总收入59.46亿元、净利润-6.76亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/02132840509599.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432617860","title":"金斯瑞生物科技盘中异动 下午盘急速拉升5.15%报12.241港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432617860","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432617860?lang=zh_cn&edition=full","pubTime":"2024-05-02 13:28","pubTimestamp":1714627681,"startTime":"0","endTime":"0","summary":"2024年05月02日下午盘13时28分，金斯瑞生物科技股票出现异动，股价大幅上涨5.15%。截至发稿，该股报12.241港元/股，成交量326.184万股，换手率0.15%，振幅7.56%。资金方面，该股资金流入2460.63万港元，流出1089.22万港元。金斯瑞生物科技股票所在的生物技术行业中，整体涨幅为1.66%。金斯瑞生物科技公司简介：金斯瑞生物科技股份有限公司是一家主要从事生物科学研究及相关业务的香港投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240502132801861eaa7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240502132801861eaa7b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432974616","title":"港股异动 | CRO概念股早盘普涨 美联储加息预期逐步减弱 创新药投融资环境有望逐步回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2432974616","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2432974616?lang=zh_cn&edition=full","pubTime":"2024-05-02 11:12","pubTimestamp":1714619577,"startTime":"0","endTime":"0","summary":"消息面上，美联储5月会议维持利率不变，鲍威尔也否定了加息选项，同时宣布缩表即将减速。湘财证券指出，虽然当前CXO受国内外医药投融资下滑影响业绩承压，但鉴于美联储加息预期逐步减弱，以及经过近两年全球biotech领域估值泡沫的出清，全球生技产业性价比已凸显，创新药投融资环境有望逐步回暖，看好CXO长期向好的短期改善。“生物制造”已经被写入2024年政府工作报告并被列为新增长引擎之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116838.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431024859","title":"CRO概念股延续近期涨势 金斯瑞生物科技涨近9%药明生物涨近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431024859","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2431024859?lang=zh_cn&edition=full","pubTime":"2024-04-29 11:34","pubTimestamp":1714361672,"startTime":"0","endTime":"0","summary":"CRO概念股延续近期涨势，金斯瑞生物科技（01548）上涨8.71%，报11.98港元；药明生物（02269）上涨5.94%，报14.28港元；康龙化成（03759）上涨5.70%，报10.02港元；维亚生物（01873）上涨5.36%，报0.59港元。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-29/doc-inatninf1488454.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-29/doc-inatninf1488454.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431702579","title":"港股异动 | CRO概念股延续反弹 下游需求端有待好转 国内CXO公司仍具备竞争优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2431702579","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431702579?lang=zh_cn&edition=full","pubTime":"2024-04-29 10:55","pubTimestamp":1714359352,"startTime":"0","endTime":"0","summary":"中信建投指出，目前医药领域一级投融资仍有待恢复，下游需求端有待好转。该行指出，国内CXO公司相比全球企业仍具备一定竞争优势，近年来在ADC、多肽药物快速发展下，相关CXO需求迅速增加，小核酸、CGT等细分领域也有望迎来快速发展。临床CRO领域匹配高端需求的公司有望获得更高份额。目前CXO板块整体估值处于低位，长期来看，我们仍旧看好CXO板块发展潜力及成长空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1113909.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431402836","title":"金斯瑞生物科技(01548)股价上升8.167%，现价港币$11.92","url":"https://stock-news.laohu8.com/highlight/detail?id=2431402836","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2431402836?lang=zh_cn&edition=full","pubTime":"2024-04-29 10:10","pubTimestamp":1714356600,"startTime":"0","endTime":"0","summary":"[上升股]金斯瑞生物科技(01548) 股价在上午10:10比前收市价上升8.167%，现股价为港币$11.92。至目前为止，今日最高价为$11.92，而最低价为$11.12。总成交量为674.06万股，总成交金额为港币$7.835千万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2404291108/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2431044827","title":"金斯瑞生物科技盘中异动 早盘急速拉升5.08%报11.581港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431044827","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431044827?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:41","pubTimestamp":1714354864,"startTime":"0","endTime":"0","summary":"2024年04月29日早盘09时41分，金斯瑞生物科技股票出现异动，股价急速拉升5.08%。截至发稿，该股报11.581港元/股，成交量221.86万股，换手率0.10%，振幅4.36%。金斯瑞生物科技股票所在的生物技术行业中，整体涨幅为0.17%。其相关个股中，药明合联、帝王国际投资、金斯瑞生物科技涨幅较大，振幅较大的相关个股有宜明昂科-B、科笛-B、药明合联，振幅分别为9.40%、9.29%、5.12%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404290941047a56de40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404290941047a56de40&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431041024","title":"金斯瑞生物科技(01548)上涨5.08%，报11.58元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431041024","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431041024?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:39","pubTimestamp":1714354762,"startTime":"0","endTime":"0","summary":"4月29日，金斯瑞生物科技(01548)盘中上涨5.08%，截至09:39，报11.58元/股，成交1945.81万元。金斯瑞生物科技股份有限公司是一家全球重要的生命科学研发与生产服务提供商，主要业务包括生命科学服务及产品、生物医药合同研发生产、工业合成产品和综合性全球细胞疗法。截至2022年12月31日，公司在全球拥有6213名员工，拥有超过210项授权专利与800多项专利申请，业务覆盖全球100多个国家和地区，为20余万客户提供服务与产品。截至2023年年报，金斯瑞生物科技营业总收入59.46亿元、净利润-6.76亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/29093940458506.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430448947","title":"交银国际：维持金斯瑞生物科技(01548)“买入”评级 目标价27.75港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430448947","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2430448947?lang=zh_cn&edition=full","pubTime":"2024-04-25 10:53","pubTimestamp":1714013581,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技(01548)指引全年收入有15%-20%和20%-30%(@CER,即比较效果研究)的强劲增长。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20240425/20240425105326_84447.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240425/20240425105326_84447.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109540.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429386175","title":"金斯瑞生物科技4月23日遭南向资金减持770.80万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429386175","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429386175?lang=zh_cn&edition=full","pubTime":"2024-04-24 09:31","pubTimestamp":1713922273,"startTime":"0","endTime":"0","summary":"4月23日，南向资金减持金斯瑞生物科技770.80万股。截止当日收盘，港股通共持有金斯瑞生物科技54078.80万股，占流通股25.45%。金斯瑞生物科技近5个交易日下跌5.67%，港股通累计减持1536.96万股；近20个交易日下跌29.25%，港股通累计减持2995.27万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404240942558b4cbb42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404240942558b4cbb42&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429184959","title":"金斯瑞(01548.HK)：传奇生物药物获欧盟批准治疗骨髓瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2429184959","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2429184959?lang=zh_cn&edition=full","pubTime":"2024-04-23 09:22","pubTimestamp":1713835320,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技的非全资附属传奇生物公布，欧盟委员会已批准CARVYKTI 用于治疗复发和难治性多发性骨髓瘤成人患者，该些患者既往接受过至少一种治疗，包括蛋白酶体抑制剂和免疫调节剂，在最后一次治疗中已证明疾病进展，并且对来那度胺难治。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20211125141320348_s.jpeg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20211125141320348_s.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1344142/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2429189305","title":"金斯瑞生物科技(01548)：传奇生物宣布欧盟委员会批准 CARVYKTI 用于复发难治性多发性骨髓瘤患者二线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2429189305","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429189305?lang=zh_cn&edition=full","pubTime":"2024-04-23 08:44","pubTimestamp":1713833040,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技(01548)发布公告，该公司非全资附属公司传奇生物已于2024年4月22日(纽约时间，于2024年4月23日香港交易时段前)向美国证监会(SEC)提交 6-K 表格，欧盟委员会已批准 CARVYKTI®(ciltacabtagene autoleucel，cilta-cel)用于治疗复发性难治性多发性骨髓瘤成年患者，这些患者此前至少接受过一种治疗(包括蛋白酶体抑制剂(PI)和一种免疫调节剂(IMiD))，患者在最后一次治疗中显示出疾病进展，并且对来那度胺耐药 。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107292.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429979409","title":"金斯瑞生物科技（1548.HK）：全球化布局，业务多点开花，创新药业务进入商业化兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2429979409","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2429979409?lang=zh_cn&edition=full","pubTime":"2024-04-22 14:17","pubTimestamp":1713766644,"startTime":"0","endTime":"0","summary":"在全球化风险因素的交织影响下，企业如何在波涛汹涌中坚守并持续向前，已然成为业界的共同难题。然而，金斯瑞似乎以一份卓越的答卷，给出了自己的独特答案。","market":"us","thumbnail":"https://img2.gelonghui.com/53bfe-caa92ee3-09d5-4a14-bd47-292a1714014e.jpg?guru_height=2160&guru_width=3840","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/53bfe-caa92ee3-09d5-4a14-bd47-292a1714014e.jpg?guru_height=2160&guru_width=3840"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/722384","is_publish_highlight":false,"gpt_icon":0},{"id":"2429961587","title":"金斯瑞生物科技盘中异动 股价大涨5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429961587","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429961587?lang=zh_cn&edition=full","pubTime":"2024-04-22 09:53","pubTimestamp":1713750800,"startTime":"0","endTime":"0","summary":"2024年04月22日早盘09时53分，金斯瑞生物科技股票出现异动，股价急速拉升5.17%。金斯瑞生物科技股票所在的生物技术行业中，整体跌幅为0.33%。其相关个股中，金斯瑞生物科技、创胜集团-B、亚盛医药-B涨幅较大，振幅较大的相关个股有科笛-B、来凯医药-B、金斯瑞生物科技，振幅分别为9.06%、5.97%、5.75%。金斯瑞生物科技公司简介：金斯瑞生物科技股份有限公司是一家主要从事生物科学研究及相关业务的香港投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404220953217a545e63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404220953217a545e63&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429961582","title":"南向资金4月19日净卖出金斯瑞生物科技33.95万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2429961582","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429961582?lang=zh_cn&edition=full","pubTime":"2024-04-22 09:31","pubTimestamp":1713749474,"startTime":"0","endTime":"0","summary":"4月19日，南向资金减持金斯瑞生物科技33.95万股连续3日减持。截止当日收盘，港股通共持有金斯瑞生物科技54792.40万股，占流通股25.79%。金斯瑞生物科技近5个交易日下跌18.18%，港股通累计减持825.76万股；近20个交易日下跌32.90%，港股通累计减持1679.87万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404220942198b43b726&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404220942198b43b726&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428680374","title":"金斯瑞生物科技04月19日收跌8.90% 主力资金逆市抢筹","url":"https://stock-news.laohu8.com/highlight/detail?id=2428680374","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428680374?lang=zh_cn&edition=full","pubTime":"2024-04-19 16:15","pubTimestamp":1713514558,"startTime":"0","endTime":"0","summary":"04月19日, 金斯瑞生物科技股价跌8.90%，报收10.44元，成交金额3.23亿元，换手率1.43%，振幅9.60%，量比2.55。金斯瑞生物科技今日主力资金净流入3082万元，上一交易日主力净流出634万元。该股近5个交易日下跌18.65%，主力资金累计净流入2448万元；近20日主力资金累计净流出1094万元，其中净流出天数为12日。该股主力净额占比0.14%，港股市场排名33/2628。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191616228794af83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191616228794af83&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428851246","title":"金斯瑞生物科技(01548)股价下跌8.202%，现价港币$10.52","url":"https://stock-news.laohu8.com/highlight/detail?id=2428851246","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2428851246?lang=zh_cn&edition=full","pubTime":"2024-04-19 14:35","pubTimestamp":1713508500,"startTime":"0","endTime":"0","summary":"[下跌股]金斯瑞生物科技(01548) 股价在下午02:34比前收市价下跌8.202%，现股价为港币$10.52。至目前为止，今日最高价为$11.44，而最低价为$10.52。总成交量为2.002千万股，总成交金额为港币$2.151亿。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2404193260/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2428570092","title":"港股异动 | CRO概念股延续跌势 美联储不排除加息可能 国内创新药仍处调整周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2428570092","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428570092?lang=zh_cn&edition=full","pubTime":"2024-04-19 10:55","pubTimestamp":1713495318,"startTime":"0","endTime":"0","summary":"消息面上，隔夜美联储官员发布鹰派言论。此外，亚特兰大联储行长博斯蒂克和明尼阿波利斯联储主席卡什卡利也释放出更为强劲的“鹰”声，加剧了市场对加息的担忧。瑞银策略师近日表示，顽固的通胀和经济强劲增长提高了美联储加息而不是降息的可能性，明年利率最高可能升至6.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1105177.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428579882","title":"金斯瑞生物科技4月18日遭南向资金减持591.07万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2428579882","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428579882?lang=zh_cn&edition=full","pubTime":"2024-04-19 09:31","pubTimestamp":1713490286,"startTime":"0","endTime":"0","summary":"4月18日，南向资金减持金斯瑞生物科技591.07万股。截止当日收盘，港股通共持有金斯瑞生物科技54826.34万股，占流通股25.81%。金斯瑞生物科技近5个交易日下跌9.76%，港股通累计减持882.61万股；近20个交易日下跌31.54%，港股通累计减持1459.65万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190942188792bdc7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190942188792bdc7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427823089","title":"金斯瑞生物科技(01548)：CARVYKTI®第一季度贸易销售净额约1.57亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427823089","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2427823089?lang=zh_cn&edition=full","pubTime":"2024-04-16 19:49","pubTimestamp":1713268159,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技(01548)发布公告，2024年4月16日，传奇生物科技股份有限公...","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_2.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_2.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103490.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0889},{"period":"1month","weight":-0.1655},{"period":"3month","weight":-0.0654},{"period":"6month","weight":-0.4655},{"period":"1year","weight":-0.4132},{"period":"ytd","weight":-0.3958}],"compareEarnings":[{"period":"1week","weight":0.0467},{"period":"1month","weight":0.1047},{"period":"3month","weight":0.1894},{"period":"6month","weight":0.046},{"period":"1year","weight":-0.0738},{"period":"ytd","weight":0.0838}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"制造及销售生命科学研究产品及服务。产品及服务主要包括生命科学研究服务、临床前药物研发服务、生命科学研究目录产品及工业合成生物产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":-0.012915},{"month":2,"riseRate":0.555556,"avgChangeRate":0.078892},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.061679},{"month":4,"riseRate":0.555556,"avgChangeRate":0.055583},{"month":5,"riseRate":0.555556,"avgChangeRate":0.075486},{"month":6,"riseRate":0.625,"avgChangeRate":0.0574},{"month":7,"riseRate":0.5,"avgChangeRate":0.012771},{"month":8,"riseRate":0.375,"avgChangeRate":0.132663},{"month":9,"riseRate":0.375,"avgChangeRate":-0.108852},{"month":10,"riseRate":0.75,"avgChangeRate":0.142825},{"month":11,"riseRate":0.75,"avgChangeRate":0.077381},{"month":12,"riseRate":0.375,"avgChangeRate":0.084334}],"exchange":"SEHK","name":"金斯瑞生物科技","nameEN":"GENSCRIPT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金斯瑞生物科技,01548,金斯瑞生物科技股票,金斯瑞生物科技股票老虎,金斯瑞生物科技股票老虎国际,金斯瑞生物科技行情,金斯瑞生物科技股票行情,金斯瑞生物科技股价,金斯瑞生物科技股市,金斯瑞生物科技股票价格,金斯瑞生物科技股票交易,金斯瑞生物科技股票购买,金斯瑞生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}